Kodiak Sciences clinical trials we track

Check company identity source

Phase 3 10 trials

TrialDrugs studiedStatusPrimary completion
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTONCT07734844Aflibercept (2.0 mg), Tabirafusp tedromerRecruiting2028-08-31Estimated
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399KSI-101, Sham ComparatorRecruiting2027-04Estimated
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLENCT06996080KSI-101, Sham ComparatorRecruiting2027-02Estimated
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368Aflibercept, Tabirafusp tedromer, Tarcocimab tedromerActive not recruiting2026-09-02Actual
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)NCT06270836Sham injection, TarcocimabCompleted2026-02-13Actual
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)NCT04964089Aflibercept, KSI-301, Sham ProcedureCompleted2023-03-28Actual
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)NCT04592419Aflibercept, KSI-301, Sham ProcedureCompleted2022-06-10Actual
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)NCT05066230KSI-301, Sham injectionTerminated2023-08-03Actual
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152Aflibercept, KSI-301, Sham ProcedureTerminated2023-05-11Actual
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04603937Aflibercept, KSI-301, Sham ProcedureTerminated2023-04-27Actual

Phase 2 / 3 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 675 participants (planned). After: 667 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 2 Sep 2026.

Check registry source

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Jan 2026. After: 13 Feb 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source